{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:17:25Z","timestamp":1792829845806,"version":"4.5.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1245\/s10434-024-15559-4","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:02:29Z","timestamp":1718636549000},"page":"5504-5506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Examining the Concordance of Patient Age Distribution between Genitourinary (GU) Clinical Trials and Real-World Disease Populations: Kidney, Prostate and Bladder Cancer Analysis"],"prefix":"10.1245","volume":"31","author":[{"given":"Emma","family":"Helstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoniy","family":"Fulmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Sindhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaha","family":"Isali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-6230","authenticated-orcid":false,"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"3","key":"15559_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/ijc.33232","volume":"148","author":"S Pilleron","year":"2021","unstructured":"Pilleron S, Soto-Perez-de-Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601\u20138. https:\/\/doi.org\/10.1002\/ijc.33232.","journal-title":"Int J Cancer."},{"issue":"10","key":"15559_CR2","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/bcp.14539","volume":"86","author":"RJ van Marum","year":"2020","unstructured":"van Marum RJ. Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol. 2020;86(10):2014\u20136. https:\/\/doi.org\/10.1111\/bcp.14539.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"15559_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber I, Ong S, Bukavina L, Black P, Comperat E, Kamat A, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84(2):176\u201390.","journal-title":"Eur Urol"},{"issue":"5","key":"15559_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","volume":"82","author":"L Bukavina","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.019.","journal-title":"Eur Urol."},{"issue":"7","key":"15559_CR5","doi-asserted-by":"publisher","first-page":"e68409","DOI":"10.1371\/journal.pone.0068409","volume":"8","author":"V Huser","year":"2013","unstructured":"Huser V, Cimino JJ. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS One. 2013;8(7):e68409.","journal-title":"PLoS One"},{"issue":"22","key":"15559_CR6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720\u20136. https:\/\/doi.org\/10.1001\/jama.291.22.2720.","journal-title":"JAMA"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15559-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T18:23:10Z","timestamp":1722882190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["15559"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15559-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pedro Barata has received honoraria from Astellas, AstraZeneca, Bayer, Eisai, Caris Life Sciences, Exelixis, Janssen, EMD Serono, Dendreon, Pfizer, Seattle Genetics, BMS, Guardant Health, Myovant, UroToday, OncLive, Targeted Oncology, and Eisai, and has undertaken contracted research for AstraZeneca, Merck, Caris Life Sciences, ESSA Pharma, Myovant, Merck, Exelixis, and Merus. Emma Helstrom, Ankita Lakshmanan, Antoniy Fulmes, Mohit Sindhani, Ilaha Isali, and Laura Bukavina consulting for Charite, UroGen Pharma. Associate Editor of European Urology, Editorial Board Member Urology Times. She has received funding from Bladder Cancer Advocacy Network and Urology Care Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}